Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer.
Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer.
复制标题
DOI：
10.1016/0042-6822(92)90453-v
复制
发表时间：
1992-04
期刊：
影响因子：
3.7
通讯作者：
Martin Moller;R. Viscidi;Yeping Sun;E. Guerrero;Peter M. Hill;F. Shah;F. X. Xavier Bosch;N. Muño
中科院分区：
文献类型：
--
作者：
Martin Moller;R. Viscidi;Yeping Sun;E. Guerrero;Peter M. Hill;F. Shah;F. X. Xavier Bosch;N. Muño
人乳头瘤病毒 (HPV) 的转化蛋白 E6 和 E7 在 HPV 相关宫颈癌中持续表达。在使用四种 HPV-16 E6-E7 肽的 ELISA 中，HPV-16 相关的浸润性宫颈癌患者（第 1 组）的血清反应性高于所有其他组，其中包括 HPV-16 相关的宫颈上皮内瘤变患者、无 HPV 的浸润性宫颈癌患者以及未受影响的对照。与所有其他组的血清相比，较大比例的第 1 组血清与至少一种肽（49% vs 17-27%）以及两种或多种肽（22% vs 0-6%）发生反应。还发现第 1 组和所有其他组之间至少一种肽的高 ELISA 吸光度值存在明显差异（22% 与 0–8%）。 1 组血清的这种高血清反应性通过体外转录和翻译的 HPV-16 E7 蛋白的放射免疫沉淀测定得到证实。在此测试中，来自第 1 组 50% 的血清（但只有 3% 的对照组）有反应。 HPV-16 E6 和 E7 蛋白的抗体似乎是 HPV 相关宫颈癌的病毒特异性和疾病状态特异性标记。
Transforming proteins E6 and E7 of human papillomaviruses (HPVs) are consistently expressed in HPV-associated cervical cancers. In ELISA with four HPV-16 E6-E7 peptides, patients with HPV-16-associated invasive cervical cancer (group 1) had a greater seroreactivity than all other groups, which included patients with HPV-16-associated cervical intraepithelial neoplasia, invasive cervical cancer patients without HPVs, and unaffected controls. A larger proportion of group 1 sera, as compared to sera of all other groups, was reactive with at least one peptide (49% vs 17–27%), and with two or more peptides (22% vs 0–6%). A clear difference between group 1 and all other groups was also found for high ELISA absorbance values to at least one peptide (22% vs 0–8%). This high seroreactivity of group 1 sera was confirmed by a radioimmunoprecipitation assay within vitrotranscribed and translated HPV-16 E7 protein. Sera from 50% of group 1 but only 3% of controls were reactive in this test. Antibodies to HPV-16 E6 and E7 proteins appear to be virus-specific and disease state-specific markers of HPV-associated cervical cancer.